NO20092102L - Krystallinformer av aliskiren hemifumarat - Google Patents

Krystallinformer av aliskiren hemifumarat

Info

Publication number
NO20092102L
NO20092102L NO20092102A NO20092102A NO20092102L NO 20092102 L NO20092102 L NO 20092102L NO 20092102 A NO20092102 A NO 20092102A NO 20092102 A NO20092102 A NO 20092102A NO 20092102 L NO20092102 L NO 20092102L
Authority
NO
Norway
Prior art keywords
informer
crystal
aliskiren hemifumarate
crystal forms
preparation
Prior art date
Application number
NO20092102A
Other languages
English (en)
Norwegian (no)
Inventor
Stephanie Monnier
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37907983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092102(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20092102L publication Critical patent/NO20092102L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20092102A 2006-11-07 2009-05-28 Krystallinformer av aliskiren hemifumarat NO20092102L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06123642 2006-11-07
PCT/EP2007/009573 WO2008061622A1 (en) 2006-11-07 2007-11-05 Crystalline forms of aliskiren hemifumarate

Publications (1)

Publication Number Publication Date
NO20092102L true NO20092102L (no) 2009-07-30

Family

ID=37907983

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092102A NO20092102L (no) 2006-11-07 2009-05-28 Krystallinformer av aliskiren hemifumarat

Country Status (25)

Country Link
US (1) US8119841B2 (es)
EP (1) EP2079463A1 (es)
JP (1) JP2010508370A (es)
KR (1) KR20090083918A (es)
CN (1) CN101594857B (es)
AR (1) AR063560A1 (es)
AU (1) AU2007323465B2 (es)
BR (1) BRPI0718546A2 (es)
CA (1) CA2668828A1 (es)
CL (1) CL2007003194A1 (es)
CO (1) CO6180428A2 (es)
EC (1) ECSP099385A (es)
GT (1) GT200900116A (es)
IL (1) IL198470A0 (es)
MA (1) MA30921B1 (es)
MX (1) MX2009004885A (es)
MY (1) MY148758A (es)
NO (1) NO20092102L (es)
NZ (1) NZ577320A (es)
PE (2) PE20121179A1 (es)
RU (1) RU2466982C2 (es)
TN (1) TN2009000174A1 (es)
TW (1) TW200827326A (es)
WO (1) WO2008061622A1 (es)
ZA (1) ZA200902941B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120029083A1 (en) * 2007-11-13 2012-02-02 Teva Pharmaceutical Industries, Ltd. Polymorphic forms of aliskiren hemifumarate and process for preparation thereof
PL2237783T3 (pl) 2008-01-23 2015-04-30 Novartis Ag Sposób optymalizacji leczenia chorób proliferacyjnych, w których pośredniczy receptor kinazy tyrozynowej kit, z użyciem imatynibu
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
JO3239B1 (ar) 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
KR20160129915A (ko) * 2008-12-18 2016-11-09 노파르티스 아게 1-[4-[1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸]-2-에틸-벤질]-아제티딘-3-카르복실산의 헤미푸마레이트 염
EA201190091A1 (ru) 2009-02-05 2012-01-30 Крка, Товарна Здравил, Д. Д., Ново Место Активируемый влагой способ грануляции
KR20110006703A (ko) * 2009-02-05 2011-01-20 테바 파마슈티컬 인더스트리즈 리미티드 알리스키렌 화합물의 고체 형태
WO2011028919A2 (en) 2009-09-03 2011-03-10 Teva Pharmaceutical Industries Ltd. Solid forms of aliskiren hemifumarate and processes for preparation thereof
CN102617392B (zh) * 2011-01-28 2015-04-01 博瑞生物医药技术(苏州)有限公司 一种阿利克仑半富马酸盐晶型ⅰ的制备方法
ITMI20111290A1 (it) * 2011-07-11 2013-01-12 Djada Pharmaceutical Sa Aliskiren emifumarato, forma cristallina e solido amorfo
ITMI20111291A1 (it) * 2011-07-11 2013-01-12 Djada Pharmaceutical Sa Aliskiren emifumarato etil acetato solvato
CN103172533B (zh) * 2011-12-20 2016-05-04 博瑞生物医药(苏州)股份有限公司 一种阿利克仑半富马酸盐的新晶型及其制备方法和用途
JP6007096B2 (ja) * 2011-12-28 2016-10-12 エルメッド エーザイ株式会社 安定化カンデサルタンシレキセチル含有物の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
KR100690471B1 (ko) 2000-07-05 2007-03-09 스페델 파르마 아게 치환된 옥타노일 아미드의 제조방법
KR20130109244A (ko) * 2002-05-17 2013-10-07 노파르티스 아게 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물
PE20060075A1 (es) * 2004-03-17 2006-03-20 Novartis Ag Composiciones farmaceuticas de alisciren
GB0419361D0 (en) 2004-08-31 2004-10-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CL2007003194A1 (es) 2008-06-13
TW200827326A (en) 2008-07-01
NZ577320A (en) 2012-01-12
MA30921B1 (fr) 2009-11-02
IL198470A0 (en) 2010-02-17
RU2466982C2 (ru) 2012-11-20
US8119841B2 (en) 2012-02-21
JP2010508370A (ja) 2010-03-18
PE20081157A1 (es) 2008-09-26
AU2007323465A1 (en) 2008-05-29
TN2009000174A1 (en) 2010-10-18
BRPI0718546A2 (pt) 2013-11-19
MY148758A (en) 2013-05-31
CO6180428A2 (es) 2010-07-19
CN101594857B (zh) 2012-10-31
PE20121179A1 (es) 2012-09-13
AR063560A1 (es) 2009-02-04
ZA200902941B (en) 2010-03-31
WO2008061622A1 (en) 2008-05-29
AU2007323465B2 (en) 2011-08-04
MX2009004885A (es) 2009-05-19
US20100048716A1 (en) 2010-02-25
GT200900116A (es) 2011-06-07
EP2079463A1 (en) 2009-07-22
ECSP099385A (es) 2009-07-31
CA2668828A1 (en) 2008-05-29
RU2009121651A (ru) 2010-12-20
KR20090083918A (ko) 2009-08-04
CN101594857A (zh) 2009-12-02

Similar Documents

Publication Publication Date Title
NO20092102L (no) Krystallinformer av aliskiren hemifumarat
CY1110813T1 (el) Χημικες ενωσεις
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
CY1112511T1 (el) Κρυσταλλικη στερεα βαση ρασαγιλινης (rasagiline)
WO2007127841A3 (en) Compositions and methods of preparation thereof
WO2006127899A3 (en) (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
DE602006008625D1 (de) Polymermicellen für die arzneistoffzufuhr
IL197161A (en) Derivatives 4- (n-azacycloalkyl) anilides Preparations containing and using them
NO20081719L (no) Displaysammenstillinger og fremgangsmater for displayvisning
WO2009015390A3 (en) Co-incuating confined microbial communities
ATE457310T1 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2009039189A3 (en) Compositions comprising stat3 sirna and methods of use thereof
WO2009155001A3 (en) Wnt protein signalling inhibitors
BRPI0716210A2 (pt) Métodos, composições e aparelhos para tratar feridas com pressões diferentes da atmosférica
WO2007125105A3 (en) Benzamide glucokinase activators
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2007106670A3 (en) N-formyl hydroxylamine compounds
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
TW200800999A (en) Novel compounds
WO2006099193A3 (en) Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
WO2007133562A3 (en) Monocyclic heteroaryl compounds
WO2007070562A3 (en) Non-hygroscopic compositions of enterostatin
WO2009002440A3 (en) Compositions comprising human egfr-sirna and methods of use
WO2008045507A3 (en) Substituted tetracycline compounds for treatment of bacillus anthracis infections

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application